UNLIMITED TURBO SHORT - NOVO-NORDISK B | Real-time Euronext Paris 12:14:36 10/06/2024 BST | ||
| 0.44 EUR | +18.92% |
|
| Current month | -69.17% | ||
| 1 month | -79.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 10/06/24 | 0.44 | +18.92% |
| 07/06/24 | 0.37 | -28.85% |
| 06/06/24 | 0.52 | -47.47% |
| 04/06/24 | 0.99 | -16.10% |
| 03/06/24 | 1.18 | -1.67% |
Real-time Euronext Paris
Last update June 10, 2024 at 12:14 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| MI7MB | |
| ISIN | NLBNPNL2MXU5 |
| Date issued | 31/01/2024 |
| Strike | 995.4 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.735 € |
|---|---|
| Lowest since issue | 0.34 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- MI7MB Certificat
